Breaking News, Collaborations & Alliances

Isis Earns $7 Million GSK Milestone

GSK adds antisense drug candidate

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

GlaxoSmithKline has added a development candidate, ISIS-GSK3, to its collaboration with Isis Pharmaceuticals, Inc., triggering a $7 million milestone payment to Isis. ISIS-GSK3 is an antisense drug designed to inhibit the production of an undisclosed target to treat a common viral infection. Isis will develop ISIS-GSK3 to Phase II proof-of-concept. GSK will then have an exclusive option to in-license the program and further development and commercialization.   Isis is eligible to earn additional...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters